Mucosal Antibodies: Defending Epithelial Barriers Against HIV-1 Invasion

Overview

Journal Vaccines (Basel)

Date 2019 Nov 28

PMID 31771162

Citations 15

Authors

Ruth M Ruprecht

Bishal Marasini

Rajesh Thippeshappa

Affiliations

Soon will be listed here.

Abstract

The power of mucosal anti-HIV-1 envelope immunoglobulins (Igs) to block virus transmission is underappreciated. We used passive immunization, a classical tool to unequivocally prove whether antibodies are protective. We mucosally instilled recombinant neutralizing monoclonal antibodies (nmAbs) of different Ig classes in rhesus macaques (RMs) followed by mucosal simian-human immunodeficiency virus (SHIV) challenge. We gave anti-HIV-1 IgM, IgG, and dimeric IgA (dIgA) versions of the same human nmAb, HGN194 that targets the conserved V3 loop crown. Surprisingly, dIgA1 with its wide-open, flat hinge protected 83% of the RMs against intrarectal R5-tropic SHIV-1157ipEL-p challenge, whereas dIgA2, with its narrow hinge, only protected 17% of the animals-despite identical epitope specificities and in vitro neutralization curves of the two dIgA isotypes (Watkins et al., 2013 27(9):F13-20). These data imply that factors in addition to neutralization determine in vivo protection. We propose that this underlying protective mechanism is immune exclusion, which involves large nmAb/virion aggregates that prevent virus penetration of mucosal barriers. Future studies need to find biomarkers that predict effective immune exclusion in vivo. Vaccine development strategies against HIV-1 and/or other mucosally transmissible pathogens should include induction of strong mucosal Abs of different Ig classes to defend epithelial barriers against pathogen invasion.

Citing Articles

PET/CT Targeted Tissue Sampling Reveals Intravenously Administered HGN194 IgG1 Affects HIV Distribution after Rectal Exposure.

Taylor R, Xiao S, Carias A, McRaven M, Thakkar D, Arainga M AIDS Res Hum Retroviruses. 2024; 40(11):637-648.

PMID: 39104250 PMC: 11876819. DOI: 10.1089/AID.2024.0019.

Immunoglobulin A response to SARS-CoV-2 infection and immunity.

Esmat K, Jamil B, Kheder R, Kombe Kombe A, Zeng W, Ma H Heliyon. 2024; 10(1):e24031.

PMID: 38230244 PMC: 10789627. DOI: 10.1016/j.heliyon.2024.e24031.

The role of tunneling nanotubes during early stages of HIV infection and reactivation: implications in HIV cure.

Valdebenito S, Ono A, Rong L, Eugenin E NeuroImmune Pharm Ther. 2023; 2(2):169-186.

PMID: 37476291 PMC: 10355284. DOI: 10.1515/nipt-2022-0015.

Cytokine Adjuvants IL-7 and IL-15 Improve Humoral Responses of a SHIV LentiDNA Vaccine in Animal Models.

Leroy L, Mac Donald A, Kandlur A, Bose D, Xiao P, Gagnon J Vaccines (Basel). 2022; 10(3).

PMID: 35335093 PMC: 8949948. DOI: 10.3390/vaccines10030461.

Vaccine with bacterium-like particles displaying HIV-1 gp120 trimer elicits specific mucosal responses and neutralizing antibodies in rhesus macaques.

Wang H, Li P, Zhang M, Bi J, He Y, Li F Microb Biotechnol. 2022; 15(7):2022-2039.

PMID: 35290714 PMC: 9249329. DOI: 10.1111/1751-7915.14022.

References

Mestecky J, Wright P, Lopalco L, Staats H, Kozlowski P, Moldoveanu Z . Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res Hum Retroviruses. 2010; 27(5):469-86. PMC: 3132065. DOI: 10.1089/aid.2010.0169. View

Brandtzaeg P, Prydz H . Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature. 1984; 311(5981):71-3. DOI: 10.1038/311071a0. View

Moser C, Amacker M, Kammer A, Rasi S, Westerfeld N, Zurbriggen R . Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines. 2007; 6(5):711-21. DOI: 10.1586/14760584.6.5.711. View

Herzog C, Hartmann K, Kunzi V, Kursteiner O, Mischler R, Lazar H . Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine. 2009; 27(33):4381-7. DOI: 10.1016/j.vaccine.2009.05.029. View

Weicker J, Underdown B . A study of the association of human secretory component with IgA and IgM proteins. J Immunol. 1975; 114(4):1337-44. View

Bonsignori M, Pollara J, Moody M, Alpert M, Chen X, Hwang K . Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 2012; 86(21):11521-32. PMC: 3486290. DOI: 10.1128/JVI.01023-12. View

Mestecky J, Jackson S, Moldoveanu Z, Nesbit L, Kulhavy R, Prince S . Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses. 2004; 20(9):972-88. DOI: 10.1089/aid.2004.20.972. View

Sholukh A, Watkins J, Vyas H, Gupta S, Lakhashe S, Thorat S . Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine. 2015; 33(17):2086-95. PMC: 4411954. DOI: 10.1016/j.vaccine.2015.02.020. View

Pastori C, Barassi C, Piconi S, Longhi R, Villa M, Siccardi A . HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket. J Biol Regul Homeost Agents. 2000; 14(1):15-21. View

10.

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

11.

Cerutti A, Puga I, Cols M . Innate control of B cell responses. Trends Immunol. 2011; 32(5):202-11. PMC: 3090458. DOI: 10.1016/j.it.2011.02.004. View

12.

Dorrell L, Hessell A, Wang M, Whittle H, Sabally S, Rowland-Jones S . Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. AIDS. 2000; 14(9):1117-22. DOI: 10.1097/00002030-200006160-00008. View

13.

Watkins J, Sholukh A, Mukhtar M, Siddappa N, Lakhashe S, Kim M . Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS. 2013; 27(9):F13-20. PMC: 4084966. DOI: 10.1097/QAD.0b013e328360eac6. View

14.

Astronomo R, Santra S, Ballweber-Fleming L, Westerberg K, Mach L, Hensley-McBain T . Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine. 2016; 14:97-111. PMC: 5161443. DOI: 10.1016/j.ebiom.2016.11.024. View

15.

Smit-McBride Z, Mattapallil J, McChesney M, Ferrick D, Dandekar S . Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J Virol. 1998; 72(8):6646-56. PMC: 109855. DOI: 10.1128/JVI.72.8.6646-6656.1998. View

16.

Breedveld A, van Egmond M . IgA and FcαRI: Pathological Roles and Therapeutic Opportunities. Front Immunol. 2019; 10:553. PMC: 6448004. DOI: 10.3389/fimmu.2019.00553. View

17.

Siddappa N, Watkins J, Wassermann K, Song R, Wang W, Kramer V . R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS One. 2010; 5(7):e11689. PMC: 2908149. DOI: 10.1371/journal.pone.0011689. View

18.

Ghys P, Belec L, Diallo M, Ettiegne-Traore V, Becquart P, Maurice C . Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Côte d'Ivoire. AIDS. 2000; 14(16):2603-8. DOI: 10.1097/00002030-200011100-00025. View

19.

Aucouturier P, Duarte F, MIHAESCO E, Pineau N, PreudHomme J . Jacalin, the human IgA1 and IgD precipitating lectin, also binds IgA2 of both allotypes. J Immunol Methods. 1988; 113(2):185-91. DOI: 10.1016/0022-1759(88)90331-6. View

20.

Baeten J, Kahle E, Lingappa J, Coombs R, Delany-Moretlwe S, Nakku-Joloba E . Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011; 3(77):77ra29. PMC: 3087186. DOI: 10.1126/scitranslmed.3001888. View